December 18, 2019
December 18, 2019 – The U.S. FDA has granted accelerated approval to PadcevTM (enfortumab vedotin-
ejfv), manufactured by Astellas and Seattle Genetics, to treat adult patients who have locally advanced or metastatic urothelial cancer. Patients must have already been treated with a platinum